Secondary malignant neoplasm of unspecified ovary
ICD-10 C79.60 is a billable code used to indicate a diagnosis of secondary malignant neoplasm of unspecified ovary.
C79.60 refers to secondary malignant neoplasms that have metastasized to the ovary from an unknown primary site. This condition indicates that cancer cells have spread to the ovarian tissue, but the original source of the cancer is not identified. Metastatic ovarian cancer can arise from various primary cancers, including breast, colon, or gastrointestinal cancers. The clinical presentation may vary, with symptoms ranging from abdominal pain, bloating, and changes in bowel habits to more systemic signs like weight loss and fatigue. Diagnosis typically involves imaging studies such as ultrasound, CT scans, or MRI, along with histopathological examination of tissue samples. Staging of metastatic disease is crucial for treatment planning and may involve the use of the FIGO staging system for ovarian cancer. Palliative care considerations are essential, focusing on symptom management and improving the quality of life for patients, especially when the disease is advanced and curative treatment options are limited.
Detailed history of the primary cancer, staging information, and treatment plans.
Patients presenting with abdominal symptoms and known history of cancer.
Accurate documentation of metastasis and treatment response is critical.
Comprehensive symptom management plans and patient quality of life assessments.
Patients with advanced cancer requiring symptom relief.
Focus on holistic care and communication with the oncology team.
Used when a biopsy of the ovarian tissue is performed to confirm metastatic disease.
Pathology report must clearly indicate the presence of metastatic cells.
Oncologists must ensure that the pathology report is linked to the diagnosis.
Coding C79.60 is crucial for accurately representing the patient's condition of secondary malignant neoplasm in the ovary, which impacts treatment decisions and healthcare resource allocation.
